TB-500 Technical Documents: COA, HPLC, Specification and Batch Review

Direct answer

A TB-500 technical-document review should begin by linking the intended product, sequence, specification, batch number and analytical evidence. For the currently published batch LJTB2026020301, the available document set consists of a Certificate of Analysis (COA), an HPLC record and a product specification. These three files should be reviewed together rather than treating a catalog purity statement or one isolated report as complete batch evidence.

The specification defines the expected tests and acceptance criteria. The COA reports results assigned to the batch. The HPLC file provides the chromatographic record used to support purity review. A separate MS or LC-MS file is not currently listed in the public batch-document set, so molecular-mass confirmation should not be inferred from the document title, URL or HPLC result. If mass-spectrometry evidence is required, it should be requested and linked to the actual batch or sample before it is relied upon.

TB-500 identity and specification baseline

The product page currently identifies the material as TB-500 and Thymosin Beta 4 peptide raw material. The following fields provide a baseline for document comparison. The transaction-specific specification, label and supplied material remain the controlling records for the buyer's review.

Field	Current product information	Document review point
Product designation	TB-500 and Thymosin Beta 4 peptide raw material	Confirm the exact designation and sequence represented by the offered material and documents.
CAS number	77591-33-4	Check consistency wherever the CAS number appears; do not use it alone to replace sequence verification.
Sequence	Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES	Confirm that the sequence and N-terminal designation match the intended 43-residue material.
Amino-acid length	43 residues	Cross-check with the stated sequence and identity documentation.
Molecular formula	C212H350N56O78S	Use with the sequence and molecular-weight information when reviewing identity evidence.
Molecular weight	4963.44 g/mol	Compare with applicable mass-related evidence if such testing is requested and supplied.
Purity specification	≥98.0% by HPLC	Compare the criterion with the batch COA and supporting HPLC record.
Storage information	Published for the supplied lyophilized form on the product page	Confirm the applicable condition on the current label, specification and shipment documents.
Testing support	Third-party laboratory testing supported	Define the requested test, sample, laboratory arrangement and report before relying on additional testing.

Current TB-500 batch document set

The following files are publicly available for batch LJTB2026020301 and show a review date of February 3, 2026. Before procurement, confirm that the lot currently offered is the same lot represented by these records.

Document	Batch	Primary review purpose	File
Certificate of Analysis	LJTB2026020301	Compare reported batch results with the specification and confirm product and batch identifiers.	View TB-500 COA
HPLC	LJTB2026020301	Review the chromatogram and purity result in relation to the COA and specification.	View TB-500 HPLC
Specification	LJTB2026020301	Identify tests, methods or method references and acceptance criteria used to evaluate the batch.	View TB-500 Specification
Separate MS or LC-MS record	Not listed in the current public set	Request batch- or sample-linked mass-spectrometry evidence when it is part of the buyer's requirements.	Confirm availability for the actual inquiry

Step 1: establish product and sequence identity

TB-500 naming is not sufficient by itself to define the material under review. Start with the full sequence, residue count, terminal designation, molecular formula and molecular weight used in the transaction. The sequence published for the current product is Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES.

Compare identifiers across the specification, COA, analytical report and label wherever they are present. If a document uses a shortened name, confirm that it still refers to the same sequence and material form. Record any difference in name, sequence notation, terminal modification or molecular information before evaluating numerical results.

Step 2: compare the specification with the COA

The specification and COA serve different functions. The specification defines the tests and acceptance criteria; the COA reports the batch results. Review them side by side and confirm:

• the product and batch identifiers are clear;
• test names, units and reporting conventions have the same meaning;
• each required result is present;
• the method or method reference corresponds to the specification;
• the purity criterion has not been replaced by a general catalog claim;
• the batch conclusion follows the reported results;
• dates and review controls are complete for the document format.

If the buyer applies an internal specification, compare it separately. Meeting the supplier specification does not automatically establish conformity with different buyer-defined criteria.

Step 3: review HPLC purity evidence

The current product information states a purity specification of at least 98.0% by HPLC. The HPLC file should be linked to batch LJTB2026020301 and read together with the corresponding COA result. Check sample identification, chromatographic conditions, detection information, retention data, integration, peak table and the final reported purity where available.

An HPLC area percentage is based on the stated method and detection conditions. It should not automatically be interpreted as peptide assay by mass, total material balance or proof that every potential impurity has been identified. Unexplained peaks, inconsistent integration or a missing batch link require clarification before the result is used for procurement decisions.

Step 4: handle MS claims correctly

Mass spectrometry can provide mass-related evidence supporting identity, but it is not interchangeable with HPLC. The current public file list for batch LJTB2026020301 does not include a separate MS or LC-MS report. Therefore, the existence, result or batch linkage of such testing should not be assumed.

When the buyer requires MS evidence, request a report that identifies the sample or batch, expected molecular information, observed ions or deconvoluted mass where applicable, charge-state interpretation, test date and reporting entity. A mass result may support identity, but it does not by itself establish chromatographic purity or compliance with every specification attribute.

Step 5: verify batch traceability and document versions

The COA, HPLC record and specification should form a traceable set. Confirm the batch or sample identifiers, report numbers, test and review dates, specification version and page completeness. If a document is corrected or replaced, the revision should be distinguishable from the earlier version.

Published records for batch LJTB2026020301 are batch-specific evidence for that lot. They may show the available document format, but they should not be presented as analytical proof for another lot. Confirm the available batch and obtain its applicable documentation before shipment.

Storage, packaging and shipment checks

Document review should extend to the supplied material form and shipment configuration. Confirm total quantity, container or aliquot arrangement, label, batch number, storage temperature, protective packaging, destination and requested transport conditions.

Storage guidance must match the supplied form. Conditions for a prepared solution should not be substituted for the unopened lyophilized material. The buyer is responsible for confirming destination-market registration, import and handling requirements.

Questions to resolve before procurement

• Which TB-500 batch is currently offered?
• Does the offered material match the published sequence and 43-residue designation?
• Do the COA, HPLC and specification identify the same batch?
• What HPLC method and reporting basis support the stated purity?
• Is separate MS or LC-MS evidence required, and is it linked to the offered batch or sample?
• What material form, quantity, packaging and aliquoting configuration are required?
• Which storage and transport conditions apply to the supplied form?
• Which documents must accompany the quality review and shipment?

Document-review warning signs

• the sequence or terminal designation is absent or inconsistent;
• the COA and HPLC file show different batch or sample identifiers;
• a purity value is provided without its applicable method or chromatogram;
• HPLC is described as complete molecular-identity confirmation;
• MS availability or results are claimed without a report linked to the sample or batch;
• the specification and COA use different criteria or units without explanation;
• a document from one batch is used to represent another batch;
• storage information for a different material form is used for the supplied product;
• regulatory or certification claims are made without current evidence.

FAQ

Which documents are currently published for TB-500 batch LJTB2026020301?

The public set includes a COA, HPLC record and specification. Confirm that the actual lot offered is the same lot represented by these files.

What should be checked first in the TB-500 documents?

Start with product designation, full sequence, terminal notation, residue count and batch linkage before comparing purity or other numerical results.

Does the HPLC result confirm TB-500 molecular identity?

Not by itself. HPLC supports chromatographic review under the stated method. Sequence and appropriate identity evidence must be considered separately.

Is an MS or LC-MS report currently published for this batch?

No separate MS or LC-MS file is listed in the current public batch-document set. Request sample- or batch-linked mass-spectrometry evidence if it is required.

Can documents for batch LJTB2026020301 represent another batch?

No. They may illustrate the document format, but batch-specific evidence applies only to the identified batch.

What should a TB-500 inquiry include?

Provide the required quantity, sequence and material-form expectations, target specification, testing and document needs, packaging, destination and schedule.

Do these records establish regulatory approval?

No. They support technical and quality review of the specified product and batch. The buyer remains responsible for registration, import and regulatory requirements in the destination jurisdiction.

Review the product and batch files

• TB-500 and Thymosin Beta 4 product technical information
• Quality documentation support
• Submit a qualified TB-500 B2B inquiry

For qualified B2B partners only. Not for personal use or direct consumer sale. Document availability, batch, quantity and supply details are confirmed for the actual inquiry.